Cutaneous events associated with immunotherapy of melanoma: A review

Abstract

Immunotherapy with checkpoint inhibitors significantly improves the outcome for stage III and IV melanoma. Cutaneous adverse events during treatment are often reported. We herein aim to review the principal pigmentation changes induced by immune check-point inhibitors: the appear-ance of vitiligo, the Sutton phenomenon, melanosis and hair and nail toxicities.